[PDF][PDF] Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories
…, B Raeder, O Bogatyrova, EM Schmitz, C Hube-Magg… - Cancer cell, 2018 - cell.com
Identifying the earliest somatic changes in prostate cancer can give important insights into
tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole …
tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole …
[HTML][HTML] Random forest-based modelling to detect biomarkers for prostate cancer progression
R Toth, H Schiffmann, C Hube-Magg, F Büscheck… - Clinical …, 2019 - Springer
Background The clinical course of prostate cancer (PCa) is highly variable, demanding an
individualized approach to therapy. Overtreatment of indolent PCa cases, which likely do not …
individualized approach to therapy. Overtreatment of indolent PCa cases, which likely do not …
[HTML][HTML] Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors
…, A Menz, AM Luebke, M Kluth, C Hube-Magg… - Biomedicines, 2021 - mdpi.com
Mesothelin (MSLN) represents an attractive molecule for targeted cancer therapies. To identify
tumors that might benefit from such therapies, tissue microarrays including 15,050 tumors …
tumors that might benefit from such therapies, tissue microarrays including 15,050 tumors …
[HTML][HTML] p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors
…, F Büscheck, AM Luebke, M Kluth, C Hube-Magg… - Biomarker …, 2021 - Springer
… Claudia Riemann … Claudia Hube-Magg …
Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers
F Person, W Wilczak, C Hube-Magg… - Tumor …, 2017 - journals.sagepub.com
Microtubules are multifunctional cytoskeletal proteins that are involved in crucial cellular roles
including maintenance of cell shape, intracellular transport, meiosis, and mitosis. Class III …
including maintenance of cell shape, intracellular transport, meiosis, and mitosis. Class III …
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre …
…, MC Tsourlakis, M Kluth, C Hube-Magg… - …, 2015 - academic.oup.com
Enhancer of zeste homolog 2 (EZH2) plays an important role in tumor development and
progression by interacting with histone and nonhistone proteins. In the current study, we …
progression by interacting with histone and nonhistone proteins. In the current study, we …
[HTML][HTML] Up-regulation of biglycan is associated with poor prognosis and PTEN deletion in patients with prostate cancer
F Jacobsen, J Kraft, C Schroeder, C Hube-Magg… - Neoplasia, 2017 - Elsevier
Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures
for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its …
for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its …
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA …
W Wilczak, S Rashed, C Hube-Magg, M Kluth… - …, 2017 - academic.oup.com
DNA mismatch repair (MMR) is integral to the maintenance of genetic stability. We aimed to
evaluate the clinical impact of MMR gene expression in prostate cancer. The MMR genes …
evaluate the clinical impact of MMR gene expression in prostate cancer. The MMR genes …
[HTML][HTML] Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors
…, F Büscheck, AM Luebke, M Kluth, C Hube-Magg… - Molecular …, 2021 - Springer
Background Cytokeratin 18 (CK18) is an intermediate filament protein of the cytokeratin acidic
type I group and is primarily expressed in single-layered or “simple” epithelial tissues and …
type I group and is primarily expressed in single-layered or “simple” epithelial tissues and …
[HTML][HTML] High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers
…, H Sirma, R Simon, C Koop, K Prien, C Hube-Magg… - Molecular …, 2013 - Elsevier
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been suggested to play a role in
cancer. To assess its role in prostate cancer, LPCAT1 expression was analyzed on a tissue …
cancer. To assess its role in prostate cancer, LPCAT1 expression was analyzed on a tissue …